The FDA recently approved the first at-home vaccine to prevent influenza, the nasal spray FluMist ... can administer the spray for children.) AstraZeneca expects to have doses ready for the ...
Irish Independent on MSN2d
Flu is leading to school absences but uptake of vaccine low – survey revealsMore than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
But the picture is mixed. A phase I trial of a nasal formulation of the Oxford AstraZeneca vaccine showed little to no induction of mucosal immunity and weaker systemic antibody responses compared ...
FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...
The Irish Patients Association is calling on parents and guardians of children to join together with them in ‘Flunion’ in the ...
PhD student Jozefien Declercq (VIB-UGent) explains: “We found that individuals who received multiple doses of mRNA vaccines exhibited a marked increase in neutralizing antibodies in nasal ...
Sales of the drug in the United States rose 19.1%, driven by strong demand in its approved indications, atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback